Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials
Abstract Background The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and would also respond to the therapeutic intervention. Objective To investigate if predictive models can be an effective tool for...
Main Authors: | Ali Ezzati, Christos Davatzikos, David A. Wolk, Charles B. Hall, Christian Habeck, Richard B. Lipton |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
Subjects: | |
Online Access: | https://doi.org/10.1002/trc2.12223 |
Similar Items
-
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
by: Wenxue Wu, et al.
Published: (2023-11-01) -
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
by: Karolina Wojtunik-Kulesza, et al.
Published: (2023-02-01) -
Advancing Alzheimer’s care: a novel therapy with lecanemab
by: Advait Teli, et al.
Published: (2023-11-01) -
Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease
by: Maria Teresa Cruz, et al.
Published: (2022-03-01) -
he amyloid hypothesis of Alzheimer's disease: past and present, hopes and disappointments
by: I. V. Litvinenko, et al.
Published: (2019-11-01)